IN2014MU00651A - - Google Patents

Download PDF

Info

Publication number
IN2014MU00651A
IN2014MU00651A IN651MU2014A IN2014MU00651A IN 2014MU00651 A IN2014MU00651 A IN 2014MU00651A IN 651MU2014 A IN651MU2014 A IN 651MU2014A IN 2014MU00651 A IN2014MU00651 A IN 2014MU00651A
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Brij Khera
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Priority to IN651MU2014 priority Critical patent/IN2014MU00651A/en
Priority to PCT/IN2015/000104 priority patent/WO2015128877A1/fr
Priority to US15/121,514 priority patent/US10925871B2/en
Publication of IN2014MU00651A publication Critical patent/IN2014MU00651A/en
Priority to PH12016501686A priority patent/PH12016501686A1/en
Priority to ZA2016/06075A priority patent/ZA201606075B/en
Priority to US17/156,809 priority patent/US20210137920A1/en
Priority to US18/480,820 priority patent/US20240024312A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
IN651MU2014 2014-02-25 2014-02-25 IN2014MU00651A (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
IN651MU2014 IN2014MU00651A (fr) 2014-02-25 2014-02-25
PCT/IN2015/000104 WO2015128877A1 (fr) 2014-02-25 2015-02-25 Compositions pharmaceutiques de sitagliptine
US15/121,514 US10925871B2 (en) 2014-02-25 2015-02-25 Pharmaceutical compositions of sitagliptin
PH12016501686A PH12016501686A1 (en) 2014-02-25 2016-08-25 Pharmaceutical compositions of sitagliptin
ZA2016/06075A ZA201606075B (en) 2014-02-25 2016-09-01 Pharmaceutical compositions of sitagliptin
US17/156,809 US20210137920A1 (en) 2014-02-25 2021-01-25 Pharmaceutical compositions of sitagliptin
US18/480,820 US20240024312A1 (en) 2014-02-25 2023-10-04 Pharmaceutical compositions of sitagliptin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN651MU2014 IN2014MU00651A (fr) 2014-02-25 2014-02-25

Publications (1)

Publication Number Publication Date
IN2014MU00651A true IN2014MU00651A (fr) 2015-10-23

Family

ID=53181316

Family Applications (1)

Application Number Title Priority Date Filing Date
IN651MU2014 IN2014MU00651A (fr) 2014-02-25 2014-02-25

Country Status (5)

Country Link
US (2) US10925871B2 (fr)
IN (1) IN2014MU00651A (fr)
PH (1) PH12016501686A1 (fr)
WO (1) WO2015128877A1 (fr)
ZA (1) ZA201606075B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019087054A1 (fr) * 2017-11-01 2019-05-09 Zenvision Pharma Llp Nouvelle composition pharmaceutique comprenant un inhibiteur de dpp-4, de l'acide alpha-lipoïque et de la vitamine b12
WO2020018034A2 (fr) 2018-04-17 2020-01-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions pharmaceutiques orales comprenant un inhibiteur de dpp-4
CN109893505B (zh) * 2019-04-18 2021-06-29 上海海洋大学 由天然植物蛋白作为载体制备包含川陈皮素的固体分散体
TR201910633A1 (tr) 2019-07-17 2021-05-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Si̇taglipti̇n i̇çeren efervesan tablet kompozi̇syonu
WO2021076066A1 (fr) * 2019-10-14 2021-04-22 Santa Farma İlaç Sanayi̇ A.Ş. Formulations orales comprenant du monohydrate de hci de sitagliptine présentant des caractéristiques pharmaceutiques améliorées
GR1010089B (el) * 2020-09-15 2021-09-27 Φαρματεν Α.Β.Ε.Ε. Στερεη φαρμακοτεχνικη μορφη περιεχουσα σιταγλιπτινη και μεθοδος παρασκευης αυτης
CN113143929B (zh) * 2021-04-15 2023-04-07 浙江诺得药业有限公司 一种西格列汀复方制剂的制备方法
CN113679684B (zh) * 2021-08-20 2023-06-16 北京鑫开元医药科技有限公司 磷酸西格列汀组合物、磷酸西格列汀片及其制备方法和用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
JO2625B1 (en) 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salts of dipeptidyl betidase inhibitor 4
EP1662876A4 (fr) 2003-09-02 2009-01-14 Merck & Co Inc Nouvelles formes cristallines d'un sel d'acide phosphorique d'un inhibiteur de dipeptidyl peptidase-iv
EP1667524A4 (fr) 2003-09-23 2009-01-14 Merck & Co Inc Nouvelle forme cristalline d'un sel d'acide phosphorique d'un inhibiteur de dipeptidyle peptase-iv
WO2005072530A1 (fr) 2004-01-16 2005-08-11 Merck & Co., Inc. Nouveau sel cristallin d'un inhibiteur de dipeptidyle peptidase-iv
US7612072B2 (en) 2004-09-15 2009-11-03 Merck & Co., Inc. Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
WO2007035198A2 (fr) 2005-07-25 2007-03-29 Merck & Co., Inc. Sel de dodecylsulfate d'un inhibiteur de la dipeptidyl peptidase iv
US9034381B2 (en) * 2005-11-10 2015-05-19 Alphapharm Pty Ltd Process to control particle size
CN101484411A (zh) 2006-06-27 2009-07-15 桑多斯股份公司 盐的新制备方法
US8334385B2 (en) 2007-11-02 2012-12-18 Glenmark Generics Limited Process for the preparation of R-sitagliptin and its pharmaceutically acceptable salts thereof
CA2707790C (fr) 2007-12-20 2015-04-21 Dr. Reddy's Laboratories Limited Procedes de preparation de sitagliptine et sels pharmaceutiquement acceptables de celle-ci
WO2009120746A2 (fr) 2008-03-25 2009-10-01 Teva Pharmaceutical Industries Ltd. Formes cristallines du phosphate de sitagliptine
US20090247532A1 (en) 2008-03-28 2009-10-01 Mae De Ltd. Crystalline polymorph of sitagliptin phosphate and its preparation
US8003672B2 (en) * 2008-04-21 2011-08-23 Merck Sharp & Dohme Corp. CB-1 receptor modulator formulations
EP2650297A1 (fr) 2008-07-03 2013-10-16 Ratiopharm GmbH Sels cristallins de sitagliptine
WO2010012781A2 (fr) 2008-07-29 2010-02-04 Medichem, S.A. Nouvelles formes cristallines de sels d’un dérivé de 5,6,7,8-tétrahydro-1,2,4- triazolo[4,3-a]pyrazine
EP2331545B1 (fr) 2008-08-27 2013-10-02 Cadila Healthcare Limited Procédé de préparation de (2r)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4]-triazolo[4,3-a]pyrazin-7(8h)-yl]-1-(2,4,5-trifluorophenyl) butan-2-amine & nouveaux impurities dans sa préparation
EA029539B8 (ru) 2011-03-29 2018-06-29 Крка, Товарна Здравил, Д.Д., Ново Место Фармацевтическая композиция ситаглиптина

Also Published As

Publication number Publication date
US20210137920A1 (en) 2021-05-13
ZA201606075B (en) 2017-08-30
US10925871B2 (en) 2021-02-23
WO2015128877A1 (fr) 2015-09-03
US20160367552A1 (en) 2016-12-22
PH12016501686A1 (en) 2016-10-03

Similar Documents

Publication Publication Date Title
BR112016017659A2 (fr)
BR112016021515A2 (fr)
BR112016017381A2 (fr)
BR112016015518A2 (fr)
BR112016019980A2 (fr)
BR112016018865A2 (fr)
BR112016021334A2 (fr)
BR112016016467A2 (fr)
BR112016027312A2 (fr)
BR112016021888A2 (fr)
BR112016030707A2 (fr)
BR112016018429A2 (fr)
CN302709846S (fr)
CN302716427S (fr)
CN302700567S (fr)
CN302701202S (fr)
CN302701738S (fr)
CN302701964S (fr)
CN302702225S (fr)
CN302702798S (fr)
CN302702898S (fr)
CN302703323S (fr)
CN302705375S (fr)
CN302709403S (fr)
CN302697317S (fr)